Analysts "see value" in $75 cash-plus bid for Genzyme

Analysts figure Sanofi-Aventis could increase the value of its offer for Genzyme to $75 in cash per share, plus $2 to $3 in contingent value rights, Bloomberg reports; the company's current bid expires at the end of the week. Report